Business Wire

LTI USD Revenue Growth Up 8.5% QoQ and 19.7% YoY; Digital Revenues at 33%

Jaa

Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q3 FY18 results today.

In US Dollars:

  • Revenue at USD 293.5 million; growth of 8.5% QoQ and 19.7% YoY
  • Constant Currency Revenue growth of 8.3% QoQ and 16.4% YoY

In Indian Rupees:

  • Revenue at Rs 18,837 million; growth of 7.6% QoQ and 13.0% YoY
  • Net Income at Rs 2,828 million; growth of 3.6% QoQ and 14.0% YoY

“Our focus remains on amplifying outcomes for our clients and establish LTI as a next generation IT services company. Large deal win momentum over the last 18 months has helped us deliver an outstanding 8.5% sequential growth in USD revenues in Q3. This superior performance has been driven by contribution from all key verticals and service offerings. Digital now contributes one-third of our overall revenues. The synergies from Syncordis acquisition are helping us initiate new conversations in Europe.”

- Sanjay Jalona, Chief Executive Officer & Managing Director, LTI

Recent Deal Wins

  • SAP Systems Integration for a large US based Specialty vehicles manufacturer
  • A Canada based development capital fund selected LTI’s proprietary record keeping platform, Unitrax for its wealth management requirements
  • Digital transformation of sales channels for a multi-national diversified conglomerate leading in Automotive parts & HVAC systems
  • Engineer-to-Order Applications portfolio engagement with a US based, Global leader in Industrial Automation
  • Fortune 100 Global Pharmaceutical corporation selected LTI for a SAP Analytics engagement
  • Robotic Process Automation engagement with one of largest mutual Life Insurers in the US
  • Digital Consulting for Applications Portfolio Rationalization and creation of AI based Chatbot for User support for a Saudi Arabia based Petrochemical company
  • Engagement with a large US based Property & Casualty Insurer to help them in their enterprise wide transformation journey to modernize core IT System by implementing Insurity

Client Testimonial

“At MPPMCL, we strive to be ahead of the curve by adopting new-age technologies. This initiative will maximise efficient power portfolio management through a technology-led decision support system. We chose LTI for this strategic engagement because of its global experience with digital transformation initiatives in the utility sector.”

- Sanjay Shukla, Managing Director, Madhya Pradesh Power Management Company Limited (MPPMCL)

Awards and Recognitions

  • Positioned as a ‘Leader’ for Digital Focus in NelsonHall’s NEAT for Digital Testing
  • Featured as High Performers in HfS Blueprint Report: Enterprise Blockchain Services 2017
  • Named Major Contender and Star Performer in Everest Group PEAK Matrix for IoT Services 2017
  • Named as one of the Breakthrough 15 Sourcing Standouts in the Americas and EMEA regions by ISG in its 4Q17 Global ISG Index™
  • Rated highly as an Innovator for S/4 HANA Focus in NelsonHall SAP NEAT 2017
  • Recognized as a Representative Vendor in Gartner’s Market Guide for Data Science and Machine Learning Service Providers 2017.*

*Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Other Business Highlights

  • LTI completed the acquisition of Syncordis
  • LTI won the Express IT Award in the Best Analytics Solution category
  • LTI won Cloudera’s ‘Partner of the Year’ Award for India
  • LTI rated among the Top 50 companies for Talent Development in the People Capital Index (PCI) survey
  • LTI CEO, Sanjay Jalona has been named as Businessworld’s Exemplary CEO of the year, 2017

About LTI

LTI (NSE: LTI, BSE: 540005) is a global technology consulting and digital solutions company helping more than 250 clients succeed in a converging world. With operations in 27 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded 20 years ago as a subsidiary of the Larsen & Toubro group, our unique heritage gives us unrivaled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 20,000 LTItes enable our clients to improve the effectiveness of their business and technology operations, and deliver value to their customers, employees and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global

Contact information

LTI
Neelian Homem
PR & Media Relations - India
+91-900-434-5540
neelian.homem@lntinfotech.com
or
Karin Bakis
PR & Media Relations - USA
+1-978-998-1578
karin.bakis@lntinfotech.com
or
Katrina Dixon
PR & Media Relations - Europe
+44-771-475-3308
Katrina.dixon@lntinfotech.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 20:15Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin

First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa22.10.2018 18:36Tiedote

Regulatory News: Inside Secure (Paris:INSD) (Euronext Paris: INSD), at the heart of security solutions for mobile and connected devices, today announced that First Data Polska S.A., a division of the global leader in commerce-enabling technology, selected Inside Secure technology to enable secure and flexible connections to Mastercard and Visa. First Data Polska S.A. chose Inside Secure’s Mobile Payment Client to easily integrate their solution with the Visa Token Service (VTS) and Mastercard Digital Enablement Service (MDES) – today’s major tokenization services that convert sensitive data into unique tokens that allow mobile payments to be processed. “Security and reliability are continual requirements for our services,” said Jolanta Rycerz, Member of Management Board at First Data Polska S.A. “We see Inside Secure as a valuable technology provider that enables us to easily migrate to the latest mobile payment technology and security standards. Thanks to Inside Secure, our customers,

PMI Launches Search for Next President and CEO22.10.2018 17:00Tiedote

Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d

E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 16:43Tiedote

E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t

Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 15:00Tiedote

Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t

Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 14:50Tiedote

To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme